UA107663C2 - Аптамер для химазы и его применение - Google Patents

Аптамер для химазы и его применение

Info

Publication number
UA107663C2
UA107663C2 UAA201200324A UAA201200324A UA107663C2 UA 107663 C2 UA107663 C2 UA 107663C2 UA A201200324 A UAA201200324 A UA A201200324A UA A201200324 A UAA201200324 A UA A201200324A UA 107663 C2 UA107663 C2 UA 107663C2
Authority
UA
Ukraine
Prior art keywords
aptamer
chymase
complex
independently represent
substance
Prior art date
Application number
UAA201200324A
Other languages
English (en)
Ukrainian (uk)
Inventor
Йошіказу Накамура
Лінг Джін
Сатоко Ямазакі
Хісако Ікеда
Масахіро Мурагучі
Original Assignee
Рібомік Інк.
Оцука Фармасьютікал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Рібомік Інк., Оцука Фармасьютікал Ко., Лтд. filed Critical Рібомік Інк.
Publication of UA107663C2 publication Critical patent/UA107663C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21039—Chymase (3.4.21.39)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Изобретение относится к аптамеру, который может связываться с химазой, для ингибирования активности химазы. Аптамер содержит нуклеотидную последовательность, представленную Х1GAUAGAN1N2UAAX2, причем Х1 и Х2 являются одинаковыми или различными и каждый из них представляет собой А G, а Ν1 и Ν2 являются одинаковыми или различными и каждый из них представляет собой A, G, С, U или Т. также заявлено комплекс, который содержит аптамеры и функциональное вещество (аффинное вещество, вещество для мечения, фермент, среду для доставки лекарственных средств, лекарственное средство и др.); лекарственное средство или реагент, содержащий аптамер или комплекс; применения аптамера для детекции и очистки химазы.
UAA201200324A 2009-06-11 2010-06-11 Аптамер для химазы и его применение UA107663C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009140585 2009-06-11
PCT/JP2010/059953 WO2010143714A1 (ja) 2009-06-11 2010-06-11 キマーゼに対するアプタマー及びその使用

Publications (1)

Publication Number Publication Date
UA107663C2 true UA107663C2 (ru) 2015-02-10

Family

ID=43308969

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201200324A UA107663C2 (ru) 2009-06-11 2010-06-11 Аптамер для химазы и его применение

Country Status (20)

Country Link
US (1) US9012420B2 (ru)
EP (1) EP2441833A4 (ru)
JP (1) JP5810356B2 (ru)
KR (1) KR20120028973A (ru)
CN (1) CN102459588B (ru)
AR (1) AR077049A1 (ru)
AU (1) AU2010259549B2 (ru)
BR (1) BRPI1010859A2 (ru)
CA (1) CA2764472A1 (ru)
CO (1) CO6480963A2 (ru)
IL (1) IL216865A0 (ru)
MX (1) MX2011013374A (ru)
MY (1) MY177984A (ru)
NZ (1) NZ597269A (ru)
RU (1) RU2579667C2 (ru)
SG (1) SG176723A1 (ru)
TW (1) TWI532842B (ru)
UA (1) UA107663C2 (ru)
WO (1) WO2010143714A1 (ru)
ZA (1) ZA201109372B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2701723B1 (en) 2011-04-28 2017-08-30 Mayo Foundation For Medical Education And Research Dna aptamers for promoting remyelination
EP2524927A1 (en) * 2011-05-20 2012-11-21 Covagen AG New chymase binding compounds and medical uses thereof
RU2633510C2 (ru) * 2011-09-28 2017-10-12 Рибомик Инк. Аптамер против ngf и его применение
JP6041288B2 (ja) * 2012-02-13 2016-12-07 国立大学法人山口大学 ホスホランバン標的修飾ｒｎａアプタマー
CN111542607A (zh) * 2017-11-09 2020-08-14 力博美科股份有限公司 针对adamts5的适配体及其应用
JP7264487B2 (ja) * 2017-11-30 2023-04-25 株式会社リボミック キマーゼに対するアプタマー及びその使用
WO2021006305A1 (ja) * 2019-07-08 2021-01-14 株式会社リボミック ＴＧＦ－β１に対するアプタマー及びその使用
KR102154683B1 (ko) * 2019-11-08 2020-09-11 주식회사 압타머사이언스 글리피칸-3 특이적 변형 압타머 및 이의 용도
CN112362626B (zh) * 2020-11-11 2021-08-27 河南农业大学 正电性Ag@Au核壳结构纳米粒子在核酸酶活性检测中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
EP1695978A1 (en) 1990-06-11 2006-08-30 Gilead Sciences, Inc. Nucleic acid ligands
DK0668931T3 (da) 1992-09-29 2006-05-22 Gilead Sciences Inc Nucleinsyreligander og fremgangsmåder til fremstilling heraf
WO1995007364A1 (en) 1993-09-08 1995-03-16 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands and improved methods for producing the same
CA2368366A1 (en) 2000-02-22 2001-08-30 Suntory Limited Medicament for prevention or treatment of fibrosis having chymase inhibitor as effective ingredient
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
EP1766042A2 (en) 2004-05-21 2007-03-28 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with chymase (cma1)
US20070099239A1 (en) * 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease

Also Published As

Publication number Publication date
AU2010259549B2 (en) 2015-10-01
AR077049A1 (es) 2011-07-27
SG176723A1 (en) 2012-01-30
BRPI1010859A2 (pt) 2016-04-05
RU2012100248A (ru) 2013-07-20
RU2579667C2 (ru) 2016-04-10
CO6480963A2 (es) 2012-07-16
WO2010143714A1 (ja) 2010-12-16
JP5810356B2 (ja) 2015-11-11
EP2441833A4 (en) 2013-03-20
US9012420B2 (en) 2015-04-21
US20120165401A1 (en) 2012-06-28
AU2010259549A1 (en) 2012-01-19
CN102459588B (zh) 2015-04-01
KR20120028973A (ko) 2012-03-23
IL216865A0 (en) 2012-02-29
EP2441833A1 (en) 2012-04-18
JPWO2010143714A1 (ja) 2012-11-29
NZ597269A (en) 2012-12-21
MX2011013374A (es) 2012-02-21
MY177984A (en) 2020-09-28
CN102459588A (zh) 2012-05-16
ZA201109372B (en) 2013-02-27
CA2764472A1 (en) 2010-12-16
TW201103983A (en) 2011-02-01
TWI532842B (zh) 2016-05-11

Similar Documents

Publication Publication Date Title
UA107663C2 (ru) Аптамер для химазы и его применение
MX2018013367A (es) Metodos para etiquetar bibliotecas codificadas por adn.
WO2011079902A3 (en) Biological inhibitors of ror1 capable of inducing cell death
NZ629701A (en) Target detection and signal amplification
MX2010008099A (es) Anticuerpos y angiopoyetina-2 estabilizados y sus usos.
MX357423B (es) Sistema de desecho de medicamento general.
WO2011008730A3 (en) Chemical modification of small hairpin rnas for inhibition of gene expression
BR112012008173A2 (pt) molécula de ligação específica de rsv
SG170802A1 (en) Systems and devices for sequence by synthesis analysis
WO2009099942A3 (en) Chemically modified oligonucleotides and uses thereof
WO2010091246A3 (en) Burstable liquid packaging and uses thereof
MX2011005934A (es) Compuestos organicos.
BR112012023315A2 (pt) compostos inibidores de enzima
GB201020995D0 (en) Biological materials and uses thereof
EP2576839A4 (en) DETECTION AND QUANTIFICATION OF NUCLEIC ACID BY POST-HYBRIDIZED MARKING AND UNIVERSAL CODING
MA33894B1 (fr) Procedes d'administration therapeutique de la pirferidone
EA201590195A1 (ru) Днк-кодированные библиотеки, содержащие связи кодирующих олигонуклеотидов, не доступные для считывания полимеразами
MX349801B (es) Sustratos de enzimas de ácido nucleico.
WO2016161375A3 (en) Methods of using oligonucleotide-guided argonaute proteins
ATE548454T1 (de) Nukleinsäurewirkstoffe zur stilllegung von h19 zwecks behandlung rheumatoider arthritis
HK1142920A1 (en) Improved purification of collagenases from clostridium histolyticum liquid culture
MX2009005148A (es) Aptamero contra midcina, y uso del mismo.
WO2014018601A3 (en) New modular base-specific nucleic acid binding domains from burkholderia rhizoxinica proteins
WO2013093347A3 (fr) Procede pour le diagnostic ou le pronostic, in vitro, du cancer de l'ovaire
IN2012DN00172A (ru)